Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.
Somer
Bradley G
BG
University of Pennsylvania Cancer Center, Philadelphia, USA. somerb@mail.med.upenn.edu
Tsai
Donald E
DE
Downs
Lisa
L
Weinstein
Barry
B
Schuster
Stephen J
SJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab